» Articles » PMID: 2234101

The Heterogeneity of the Neuronal Distribution of Exogenous Noradrenaline in the Rat Vas Deferens

Overview
Specialty Pharmacology
Date 1990 Aug 1
PMID 2234101
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

After loading of the incubated rat vas deferens with 0.2 mumol/l 3H-noradrenaline (followed by 100 min of wash-out with amine-free solution), the efflux of endogenous and exogenous compounds was determined by HPLC with electrochemical detection and by column chromatography with scintillation counting. Two different types of heterogeneity of labelling were found. The first one is due to the preferential labelling of varicosities close to the surface of the tissue, the second one to the preferential labelling of vesicles close to the surface of loaded varicosities. As diffusion distances within the tissue and within varicosities are then longer for endogenous than for exogenous amine and metabolites, the composition of spontaneous efflux of exogenous compounds differed from that for endogenous compounds. Because of preferential neuronal and vesicular re-uptake of endogenous noradrenaline, the percentage contribution by noradrenaline to overall efflux was: endogenous less than exogenous. While 3H-DOPEG was the predominant exogenous metabolite, DOPEG and MOPEG equally contributed to the "endogenous" efflux. Desipramine abolished the consequences of the first heterogeneity of labelling, i.e., it increased the efflux more for endogenous than for exogenous noradrenaline; moreover it decreased the efflux of 3H-DOPEG, but increased that of 3H-MOPEG. The reserpine-like compound Ro 4-1284, on the other hand, abolished the consequences of the second type of heterogeneity; it reduced the specific activity of "total efflux" (i.e., of the sum of noradrenaline + DOPEG + MOPEG) to the specific activity of the tissue noradrenaline. The degree of heterogeneity of labelling was reduced after inhibition of monoamine oxidase and also when the tissues were loaded with 2 or 20 mumol/l 3H-noradrenaline. It is proposed that the various "compartments" and "pools" of noradrenaline described in the literature reflect the two heterogeneities described here.

Citing Articles

Physiological and pharmacological aspects of the vas deferens-an update.

Koslov D, Andersson K Front Pharmacol. 2013; 4:101.

PMID: 23986701 PMC: 3749770. DOI: 10.3389/fphar.2013.00101.


Inhibition of purinergic transmission by prostaglandin E1 and E2 in the guinea-pig vas deferens: an electrophysiological study.

Brock J, Cunnane T Br J Pharmacol. 1996; 118(3):776-82.

PMID: 8762107 PMC: 1909739. DOI: 10.1111/j.1476-5381.1996.tb15467.x.


Homogeneous or heterogeneous distribution of systemically administered adrenaline: organ dependence.

Brandao F, Paiva M, Albino-Teixeira A, Serrao P, Guimaraes S Naunyn Schmiedebergs Arch Pharmacol. 1996; 353(5):579-83.

PMID: 8740153 DOI: 10.1007/BF00169179.


Release and disposition of 3H-noradrenaline in the saphenous vein of neonate and adult dogs.

Moura D, Azevedo I, Brandao F, Guimaraes S Naunyn Schmiedebergs Arch Pharmacol. 1993; 347(2):186-91.

PMID: 8474538 DOI: 10.1007/BF00169265.


Chronic inhibition of monoamine oxidase type A increases noradrenaline release in rat frontal cortex.

Finberg J, Pacak K, Kopin I, Goldstein D Naunyn Schmiedebergs Arch Pharmacol. 1993; 347(5):500-5.

PMID: 8391652 DOI: 10.1007/BF00166742.


References
1.
Schomig E, Trendelenburg U . Simulation of outward transport of neuronal 3H-noradrenaline with the help of a two-compartment model. Naunyn Schmiedebergs Arch Pharmacol. 1987; 336(6):631-40. DOI: 10.1007/BF00165753. View

2.
Mack F, Bonisch H . Dissociation constants and lipophilicity of catecholamines and related compounds. Naunyn Schmiedebergs Arch Pharmacol. 1979; 310(1):1-9. DOI: 10.1007/BF00499868. View

3.
Azevedo I, Moura D, Trendelenburg U . Autoradiographic study of the rat vas deferens incubated with 3H-noradrenaline. Naunyn Schmiedebergs Arch Pharmacol. 1990; 342(2):245-8. DOI: 10.1007/BF00166972. View

4.
Hughes J . Differential labelling of intraneuronal noradrenaline stores with different concentrations of (-)-3H-noradrenaline. Br J Pharmacol. 1973; 47(2):428-30. PMC: 1776551. DOI: 10.1111/j.1476-5381.1973.tb08342.x. View

5.
Langeloh A, Bonisch H, Trendelenburg U . The mechanism of the 3H-noradrenaline releasing effect of various substrates of uptake1: multifactorial induction of outward transport. Naunyn Schmiedebergs Arch Pharmacol. 1987; 336(6):602-10. DOI: 10.1007/BF00165750. View